stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Free cash flow
Arrowhead Pharmaceuticals, Inc.'s free cash flow for fiscal 2025 was $156.9M, compared with −$604.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$75.1M. Over the past ten years it has ranged from −$604.3M (fiscal 2024) to $161.0M (fiscal 2019); the current reading is higher than 91% of that period. Arrowhead Pharmaceuticals, Inc. ranks 405th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $156.9M | — |
| FY2024 | −$604.3M | — |
| FY2023 | −$330.6M | — |
| FY2022 | −$188.9M | — |
| FY2021 | $147.7M | — |
| FY2020 | −$107.8M | — |
| FY2019 | $161.0M | — |
| FY2018 | −$48.6M | — |
| FY2017 | −$31.9M | — |
| FY2016 | −$68.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$181.3M | — |
| Mar 2026 | $81.9M | 622.47% |
| Dec 2025 | $11.3M | (12.84%) |
| Sep 2025 | $13.0M | — |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $310.1M |
| CORT Corcept Therapeutics Incorporated compare | $194.6M |
| PTGX Protagonist Therapeutics, Inc. compare | $130.6M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| ARWR Arrowhead Pharmaceuticals, Inc. | −$75.1M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$168.7M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| CYTK Cytokinetics, Incorporated compare | −$588.6M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement